Metagenomi Therapeutics Inc. Common Stock (MGX)
Stock · NASDAQ · Health Care
$0.7975as of 10/16/2026
Price chart
Active signals
MGX Signal Track Record
How signals performed across all stocks →What MGX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 14 | -5.1% | 36% | October 7, 2026 |
| Bollinger Band BreakdownActive now | 9 | -4.2% | 22% | October 2, 2026 |
| Bollinger Band Breakout | 9 | -8.3% | 22% | July 7, 2026 |
| Any 20-session window (baseline) | -5.0% | 33% |
Computed by MarketWall from daily closing prices since November 22, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MGX
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hype…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 113
- Website
- metagenomi.co/
Fundamentals
- 1-day range
- $0.8001$0.86
- Market cap
- $46.68M
- P/E (trailing)
- —
- P/E (forward)
- -0.44
- EPS (trailing)
- $-2.30
- Dividend yield
- —
- Beta
- 0.70
- Avg. volume
- 156.8K
How Metagenomi Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Metagenomi Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MGXMetagenomi Therapeutics Inc. Common Stock$0.784▼ 7.22%Market cap $46.68MP/E —$0.86$3.95
- EXOZeXoZymes Inc. Common Stock$4.09▲ 2.25%Market cap $47.57MP/E —$4.35$18.4
- ATYRaTyr Pharma Inc. Common Stock$0.174▼ 5.43%Market cap $49.22MP/E —$0.2$1.11
- TILInstil Bio Inc. Common Stock$5.91▼ 3.59%Market cap $49.37MP/E —$5.67$21.64
- TCRXTScan Therapeutics Inc. Common Stock$0.231▼ 3.35%Market cap $49.88MP/E —$0.2243$2.57
- INMBINmune Bio Inc. Common stock$1.57▼ 4.85%Market cap $50.78MP/E —$1.09$2.6
- TVGNTevogen Inc. Common Stock$7.07▼ 0.14%Market cap $41.58MP/E —$3.64$39
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MGX Metagenomi Therapeutics Inc. Common Stock | $46.68M | — | $0.784 | ▼ 7.22% | $0.86$3.95 |
| EXOZ eXoZymes Inc. Common Stock | $47.57M | — | $4.09 | ▲ 2.25% | $4.35$18.4 |
| ATYR aTyr Pharma Inc. Common Stock | $49.22M | — | $0.174 | ▼ 5.43% | $0.2$1.11 |
| TIL Instil Bio Inc. Common Stock | $49.37M | — | $5.91 | ▼ 3.59% | $5.67$21.64 |
| TCRX TScan Therapeutics Inc. Common Stock | $49.88M | — | $0.231 | ▼ 3.35% | $0.2243$2.57 |
| INMB INmune Bio Inc. Common stock | $50.78M | — | $1.57 | ▼ 4.85% | $1.09$2.6 |
| TVGN Tevogen Inc. Common Stock | $41.58M | — | $7.07 | ▼ 0.14% | $3.64$39 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Reid Laurence · September 9, 2026 · Buy117 @ $1.18
- Reid Laurence · September 9, 2026 · Buy19.9K @ $1.17
- Wein Matthew · September 8, 2026 · Sale358 @ $1.16
- Irish Jian · September 8, 2026 · Sale2.1K @ $1.16
- Wapnick Pamela · September 8, 2026 · Sale1.9K @ $1.16
- Eckhardt Juergen · June 9, 2026 · Grant21.0K
- Reid Laurence · June 9, 2026 · Grant17.4K
- Willard H. Dere · June 9, 2026 · Grant21.0K
- Eric Bjerkholt · June 9, 2026 · Grant21.0K
- Wapnick Pamela · June 5, 2026 · Sale2.9K @ $1.3
- Irish Jian · June 5, 2026 · Sale3.7K @ $1.3
- Wein Matthew · June 5, 2026 · Sale558 @ $1.3
Institutional Ownership
March 31, 2026
- Total shares held
- 6.28M
- Total value held
- $8.39M
- Institutional holders
- 45
- Unknown1.06M
- Unknown787.9K
- Unknown529.0K
- Unknown516.8K
- Unknown496.8K
- Unknown395.8K
- Unknown382.2K
- Unknown358.2K
- Unknown264.4K
- Unknown230.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Metagenomi Therapeutics to Speak at Chardan Healthcare Conference
Metagenomi Therapeutics announced it will participate in the Chardan 10th Annual Healthcare Conference. This event provides a platform for the company to share updates with industry professionals and investors. The stock is currently trading near its 52-week low, making this upcoming presentation a notable point of interest for observers tracking the company's developments.
Metagenomi Therapeutics to Speak at Chardan Healthcare Conference. Metagenomi Therapeutics announced it will participate in the Chardan 10th Annual Healthcare Conference. This event provides a platform for the company to share updates with industry professionals and investors. The stock is currently trading near its 52-week low, making this upcoming presentation a notable point of interest for observers tracking the company's developments.